Synthesis, Structure Elucidation, Antibacterial Activities, and Synergistic Effects of Novel Juglone and Naphthazarin Derivatives Against Clinical Methicillin-Resistant
MIC determination
antibacterial
clinical MRSA
juglone
naphthazarin
structure elucidation
synergistic studies
Journal
Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
09
2021
accepted:
27
09
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
Infections caused by drug-resistant bacteria are a serious threat to human and global public health. Moreover, in recent years, very few antibiotics have been discovered and developed by pharmaceutical companies. Therefore, there is an urgent need to discover and develop new antibacterial agents to combat multidrug-resistant bacteria. In this study, two novel series of juglone/naphthazarin derivatives (43 compounds) were synthesized and evaluated for their antibacterial properties against various clinical and reference Gram-positive MSSA, clinical Gram-positive MRSA, and clinical and reference Gram-negative bacteria
Identifiants
pubmed: 34869221
doi: 10.3389/fchem.2021.773981
pii: 773981
pmc: PMC8640087
doi:
Types de publication
Journal Article
Langues
eng
Pagination
773981Informations de copyright
Copyright © 2021 Duvauchelle, Majdi, Bénimélis, Dunyach-Rémy, Meffre and Benfodda.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lett Appl Microbiol. 2019 Jul;69(1):41-49
pubmed: 31044446
Trends Microbiol. 2013 Mar;21(3):111-3
pubmed: 23473628
J Med Chem. 2016 Oct 13;59(19):8830-8847
pubmed: 27575438
J Nat Prod. 2002 Dec;65(12):1857-62
pubmed: 12502328
Int J Mol Sci. 2016 Jun 18;17(6):
pubmed: 27322260
Org Lett. 2018 Nov 2;20(21):6863-6867
pubmed: 30354158
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
J Med Chem. 2019 Oct 10;62(19):8665-8681
pubmed: 31063379
MethodsX. 2019 Jan 10;6:156-161
pubmed: 30733928
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14494-9
pubmed: 25246554
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
J Appl Crystallogr. 2015 Jan 30;48(Pt 1):3-10
pubmed: 26089746
Angew Chem Int Ed Engl. 1999 Feb 1;38(3):270-301
pubmed: 29711637
J Membr Biol. 2015 Aug;248(4):651-69
pubmed: 25675910
Nat Rev Microbiol. 2008 Dec;6(12):893-903
pubmed: 18997824
J Med Microbiol. 1988 Nov;27(3):215-24
pubmed: 3193444
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
Curr Opin Microbiol. 2011 Oct;14(5):564-9
pubmed: 21873107
Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):3-8
pubmed: 25567568
Med Sci (Paris). 2010 Nov;26(11):925-9
pubmed: 21106173
Chem Pharm Bull (Tokyo). 2020;68(1):46-57
pubmed: 31902901
Front Microbiol. 2019 Apr 01;10:539
pubmed: 30988669
Trends Microbiol. 2016 Nov;24(11):862-871
pubmed: 27430191